Text Size

Evaluation of Systane Balance in Dry Eye Subjects With Lipid Deficiency

This study is currently recruiting participants.
Verified May 2013 by Alcon Research
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT01688726
First received: September 17, 2012
Last updated: May 2, 2013
Last verified: May 2013
History of Changes
  Purpose

The purpose of this study is to evaluate the repeated use of SYSTANE BALANCE in dry eye sufferers who present with lipid deficiency.


Condition Intervention
Dry Eye Syndrome
Lipid Deficiency
 Other: SYSTANE BALANCE eyedrops
Other: Minims Saline 0.9% eyedrops

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Systane Balance on Conjunctival Staining (CS) Visual Performance (VP) and Tear Film Kinetics (TFK) in Dry Eye Subjects With Lipid Deficiency

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Bulbar conjunctival staining [ Time Frame: One month ] [ Designated as safety issue: No ]
    The conjunctival staining present in the bulbar area will be evaluated 120 minutes post eyedrop instillation using a slit lamp with digital image capture and lissamine green strips. The extent of true staining (the number of puncti and their individual size and the total area of coverage) will be measured and compared to the total area.


Secondary Outcome Measures:
  • High contrast logMAR time controlled visual acuity (TCVA) [ Time Frame: One month ] [ Designated as safety issue: No ]
    This visual acuity test will be carried out prior to eyedrop instillation and at 60, 90, and 120 minutes post eyedrop instillation with the subject's up-to-date vision correction in place. For each acuity level, 20 single optotypes will be presented at 4 meters under high illumination, and the percentage of correctly identified will constitute the score.

  • Non invasive tear film break-up-time (NIBUT) [ Time Frame: One month ] [ Designated as safety issue: No ]
    This assessment will be carried out prior to eyedrop instillation and at 60, 90, and 120 minutes post eyedrop instillation. The time elapsed between eye opening after a blink and the appearance of the first dark spot within the tear film, as observed with a specialized illumination source, will be recorded.


Estimated Enrollment: 90
Study Start Date: December 2012
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SYSTANE BALANCE
One drop four times a day for a continuous period of one month
 Other: SYSTANE BALANCE eyedrops
One drop in the morning; one drop early afternoon; one drop late afternoon; one drop in the evening
Active Comparator: Minims Saline
One drop four times a day for a continuous period of one month
 Other: Minims Saline 0.9% eyedrops
One drop in the morning; one drop early afternoon; one drop late afternoon; one drop in the evening

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Non-contact lens wearer;
  • Symptomatology as defined by the Ocular Surface Disease Index (OSDI) questionnaire;
  • Lipid deficiency;
  • Best visual acuity of 6/9 or better in each eye;
  • Willingness to adhere to the instructions set in the clinical protocol;
  • Signature of the subject informed consent form;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Use of systemic medication which might produce dry eye side effects;
  • Systemic disease which might produce dry eye side effects;
  • Active or recent ocular inflammation or infection;
  • Use of ocular medication;
  • Significant ocular anomaly;
  • Previous ocular surgery;
  • Previous use of Restasis;
  • Any medical condition that might be prejudicial to the study;
  • Pregnant or lactating;
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01688726

Contacts
Contact: Severine Durier, Mgr +33 1 47 10 48 43 severine.durier@alconlabs.com

Locations
United Kingdom
Recruiting
London, United Kingdom, SW1E 6AU
Sponsors and Collaborators
Alcon Research
Investigators
Principal Investigator: Michel Guillon, PhD, FCOptom, FAAO, CCTI OTG Research & Consultancy
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01688726     History of Changes
Other Study ID Numbers: A00977
Study First Received: September 17, 2012
Last Updated: May 2, 2013
Health Authority: United Kingdom: Ethics Committee

Keywords provided by Alcon Research:
Dry eye
Ocular surface
Vision complaint
 Tear film stability
Time controlled functional visual acuity
Tear film kinetics

Additional relevant MeSH terms:
Lacrimal Apparatus Diseases
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Tetrahydrozoline
 Nasal Decongestants
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Respiratory System Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013